ArticleBreast cancer research and treatment2026
Provider level facilitators and barriers towards neoadjuvant chemotherapy for triple negative and HER2 + breast cancer: a survey of Ontario surgeons.
Gary Ko et al.PubMed ↗Publisher ↗
No numbers read from the abstract.